Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program)

Trial Profile

Optimal strategy in K-ras wild type metastatic colorectal cancer patients: cetuximab plus FOLFIRI followed by FOLFOX+/- cetuximab (GOIM multicenter program)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms CAPRI-GOIM
  • Most Recent Events

    • 11 Oct 2016 Results of a post-hoc subgroup analysis (according to age) presented at the 41st European Society for Medical Oncology Congress.
    • 14 Apr 2016 Status changed from recruiting to discontinued.
    • 12 Mar 2016 Primary endpoint has not been met. (Progression-free survival duration), as per an article published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top